|
1
|
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
|
Cancer Res
|
2005
|
1.84
|
|
2
|
Aromatase, aromatase inhibitors, and breast cancer.
|
J Steroid Biochem Mol Biol
|
2011
|
1.36
|
|
3
|
Therapeutic observations in MCF-7 aromatase xenografts.
|
Clin Cancer Res
|
2005
|
1.06
|
|
4
|
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
|
J Steroid Biochem Mol Biol
|
2005
|
1.02
|
|
5
|
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.
|
Mol Cancer Ther
|
2008
|
0.99
|
|
6
|
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
|
BMC Cancer
|
2011
|
0.94
|
|
7
|
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.93
|
|
8
|
Aromatase inhibitors and breast cancer.
|
Ann N Y Acad Sci
|
2009
|
0.91
|
|
9
|
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
|
Cancer
|
2008
|
0.89
|
|
10
|
Aromatase resistance mechanisms in model systems in vivo.
|
J Steroid Biochem Mol Biol
|
2009
|
0.86
|
|
11
|
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
|
Urol Oncol
|
2008
|
0.84
|
|
12
|
Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
|
J Med Chem
|
2008
|
0.83
|
|
13
|
Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
|
Breast Cancer Res Treat
|
2013
|
0.81
|
|
14
|
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
|
Breast Cancer Res
|
2014
|
0.79
|
|
15
|
Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.
|
Clin Cancer Res
|
2011
|
0.78
|
|
16
|
mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.
|
Future Oncol
|
2014
|
0.78
|
|
17
|
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
|
Horm Mol Biol Clin Investig
|
2011
|
0.78
|
|
18
|
Synthesis and in vitro characterization of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]-trastuzumab conjugates targeted to breast cancer.
|
Macromol Biosci
|
2011
|
0.76
|
|
19
|
Advances in mechanisms of resistance to aromatase inhibitors.
|
Expert Rev Anticancer Ther
|
2014
|
0.76
|
|
20
|
Prepubertal gynaecomastia caused by medication or the aromatase excess syndrome.
|
Clin Endocrinol (Oxf)
|
2004
|
0.76
|
|
21
|
Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival.
|
Horm Mol Biol Clin Investig
|
2010
|
0.75
|